65-OR: Continuous Glucose Monitoring Metrics and Suboptimal Pregnancy Outcomes in Women with Gestational Diabetes—Secondary Analysis of the DiGest Trial

• DOI: 10.2337/db24-65-or
• Publication Date: 2024-06-14T07:29:54Z
• Authors: LAURA C. KUSINSKI; DANIELLE JONES; NOORIA ATTA; ELIZABETH TURNER; LINDA M. OUDE GRIEP; KIRSTEN L. RENNIE; EMANUELLA DE LUCI...; HELEN R. MURPHY; ROY TAYLOR; CLAIRE L. MEEK
• Keywords: Neonatal hypoglycemia

Background: Continuous glucose monitoring (CGM) is increasingly used in gestational diabetes but the optimal metrics and targets this population are undefined. We assessed if CGM were associated with pregnancy outcomes diabetes. Methods: 432 women (BMI >25 kg/m2) received a dietary intervention (DiGest trial; ISRCTN; 37866), masked (Dexcom G6) at 29 (n=332) 36wks (n=225) respectively. logistic regression, adjusted for trial arm, to assess associations between standardized outcomes, including preeclampsia, preterm delivery, large-for-gestational-age (LGA), admission neonatal intensive care unit (NICU) hypoglycemia. Time range (TIR) was defined using 63-120 mg/dl. Results: At 29wks, mean glucose, TIR time-above-range (TAR) significantly multiple pre-eclampsia, LGA, NICU hypoglycemia (table 1). TAR recalculated 63-140mg/dl (3.5-7.8 mmol/l) performed similarly. Glucose SD LGA. Time-below-range Conclusions: strong predictors of relevant Disclosure L.C. Kusinski: None. D. Jones: N. Atta: E. Turner: L.M. Oude Griep: K.L. Rennie: De Lucia Rolfe: H.R. Murphy: Advisory Panel; Medtronic. Research Support; Abbott, Dexcom, Inc. Speaker's Bureau; Ypsomed AG, Eli Lilly Company, R. Taylor: Fast800. C.L. Meek: Funding Diabetes UK 17/0005712EFSD - NNF NNF19SA058974